Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement